Literature DB >> 30374020

Author Correction: Activation of endothelial β-catenin signaling induces heart failure.

Akito Nakagawa1, Atsuhiko T Naito2,3,4,5, Tomokazu Sumida6,7, Seitaro Nomura6, Masato Shibamoto1, Tomoaki Higo1, Katsuki Okada1, Taku Sakai1, Akihito Hashimoto1, Yuki Kuramoto1, Toru Oka1, Jong-Kook Lee7,8, Mutsuo Harada6, Kazutaka Ueda6, Ichiro Shiojima9, Florian P Limbourg10, Ralf H Adams11, Tetsuo Noda12, Yasushi Sakata1, Hiroshi Akazawa6,7, Issei Komuro13,14.   

Abstract

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

Entities:  

Year:  2018        PMID: 30374020      PMCID: PMC6206138          DOI: 10.1038/s41598-018-34062-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Correction to: Scientific Reports 10.1038/srep25009, published online 05 May 2016 This Article contains incorrect echocardiographic data for Bmx/CA mice at 56w, which should be removed in Figure 2c and Supplementary Table 1. In addition, the LVFS values for 40w, 48w, 52w, 56w and 60w in Supplementary Table 1 are duplicates of the LVFS values for 16w, 20w, 24w, 28w and 32w, respectively. The correct Figure 2c is presented below as Figure 1 and the correct Supplementary Table S1 is linked to this Article.
Figure 1

Activation of β-catenin signaling in ECs causes heart failure. (c) Cardiac function of the mice was evaluated by echocardiography before, 3rd and 5th day of TAM treatment, and at the indicated time point. **P < 0.01 versus Ctrl.

Activation of β-catenin signaling in ECs causes heart failure. (c) Cardiac function of the mice was evaluated by echocardiography before, 3rd and 5th day of TAM treatment, and at the indicated time point. **P < 0.01 versus Ctrl. Supplementary Table S1
  1 in total

1.  Effect of Secreted Frizzled-Related Protein 5 in Mice with Heart Failure.

Authors:  Pan Hong; Lijie Wang; Hongchao Wang; Min Shi; Bingyan Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-31       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.